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Underlying Pathophysiology

Introduction
• Pulmonary arterial hypertension (PAH) is characterized by

 PAH is a disease that mostly affects the small resistance pulmonary arteries shown

Implications for Nursing Care
 Nursing play a huge role in educating patients and family about

persistently elevated pressures in the pulmonary arteries

by intimal hyperplasia, medial hypertrophy, adventitial proliferation, localized

the condition. Newly diagnosed PAH patients need information

(Poch, 2016).

thrombosis, and inflammation (Prins & Thenappan, 2016).

and education regarding the disease tailored to them and given

• PAH is a rare disease with about 500 - 1000 new cases a

 PAH can be idiopathic, hereditable, drug and toxin-induced, or associated with

year in the U.S. The prevalence of PAH is equal among all

connective tissue diseases, HIV infections, portal hypertension, congenital heart

ethnicities and races (Raredisease.org, 2020).

disease, and schistosomiasis (Prins & Thenappan, 2016).

• PAH can be life-threatening with a general life expectancy
of 5 years if left untreated or treated inadequately, making

 The gene involved in the hereditary PAH is the BMPR2 gene. The BMPR2 gene
(Figure1 Sysol & Machado, 2018)

early diagnosis and treatment crucial for patients and

Signs and Symptoms

healthcare providers (Poch, 2016).
• As a former cardiac nurse who has taken care of PAH
patients, and witnessed how devastating the disease is
even with treatment, I feel the need to bring awareness to
early diagnosis and treatment.

Diagnosis
• PAH can be challenging to diagnose due to non-specific
presenting symptoms (Ricketts & Church, 2017).
• The average time between the onset of symptoms and
diagnosis of PAH ranges anywhere from 18-32 months (Prins
& Thenappan, 2016).
• Right heart catheterization is regarded as the gold standard
for PAH diagnosis as it provides the hemodynamic data that
defines the disease (Pristera, Musarra, Schilz, & Hoit, 2015).
• Echocardiography, although not considered the gold

 PAH can be challenging to diagnose due to non-specific signs

controls the number of cells in certain tissues. Mutation in the gene increases cell

continuous IV therapies such as Epoprostenol due to the short

division or cell death leading to excessive growth of cells in the small arteries in the

half-life of the drug (Smith, York, Kane, & Weitendorf, 2015).

lungs (NIH, 2017).
 The excessive growth from the BMPR2 gene mutations narrows the small pulmonary

pulmonary vascular resistance that can lead to acute heart

resistance (NIH, 2020).

failure and death (Ricketts & Church, 2017).

 Lethargy

 There is persistent elevation in the right ventricle (RV) afterload as a result of

 Malaise

such as line infections, thrombosis, and embolism (Ricketts

 Dyspnea

(Prins & Thenappan, 2016).

&Church, 2017).

 The disease process of PAH includes pulmonary vascular dysfunction associated

 Development of Tricuspid regurgitation

pulmonary arteries. The imbalance has been shown to favor the vasoconstricting

& Norren, 2018).

 Increased intensity of the second heart sound

activity, which causes the small pulmonary arteries to constrict ( Prins & Thenappan,

 Peripheral edema, ascites, and elevated jugular venous pressure

2016).

left ventricle fails.

Significance of Pathophysiology

Functional
class
I

Symptomatic profile

Patients with pulmonary hypertension but without resulting
limitation of physical activity. Ordinary physical activity does not
cause dyspnea or fatigue, chest pain, or near syncope

II

 Nurses caring for PAH patients need to monitor them for signs
and symptoms of RV failure (Leeper & Powell, 2019).

of less than 60 mmHg (Leeper & Powell, 2019).
 The nurse must report adverse medication reactions to the

 PAH is a complex disease that requires expert care (Ricketts & Church, 2017).

provider and give as-needed medications to reduce adverse

 The condition ends up affecting all the major organs of the body. The main issue with

reactions like nausea and diarrhea (Leeper & Powell, 2019).

PAH is right-sided heart failure which then causes a more complicated clinical

 Nurses caring for PAH patients need to do a full head-to-toe

syndrome that affects multi-organ systems such as the left heart, brain, kidney, liver,

assessment and report any changes to providers (Leeper &

gastrointestinal tract, skeletal muscle, endocrine, immune, and autonomic systems

Powell, 2019).

(Rosankranz, Howard, Gomberg-Maitland, & Hoeper, 2020).

Conclusions

Patients with pulmonary hypertension resulting in slight limitation
of physical activity. They are comfortable at rest. Ordinary physical
activity causes undue dyspnea or fatigue, chest pain, or near
syncope

 PAH is a life-threatening disease with a general life expectancy of
5 years if left untreated or treated inadequately, making early

III

diagnosis and treatment crucial for patients and healthcare

Patients with pulmonary hypertension resulting in marked limitation
of physical activity. They are comfortable at rest. Less than
ordinary activity causes undue dyspnea or fatigue, chest pain, or
near syncope

providers (Poch, 2016).
 PAH disease-targeted therapy can only be started by doctors in

hypoxia, (4) chronic thromboembolic PH, and (5) PH with
IV

specialist centers who specialize in treating PAH (Ricketts &

Patients with pulmonary hypertension with inability to carry out
any physical activity without symptoms. These patients manifest
signs of right heart failure. Dyspnea and/or fatigue may even be
present at rest. Discomfort is increased by any physical activity

Church, 2017).
 The initial signs and symptoms can be vague, which delays
prompt diagnosis (Ricketts & Church, 2017).

class I is considered the mildest form of the disease, and
(Table 1. WHO functional classification of pulmonary arterial
hypertension. (Ricketts & Church, 2017)

(Figure 2. Classification of pulmonary hypertension, WHO 2008 (modified and not exhaustive)1
(Ricketts & Church, 2017).
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 Monitor oxygenation levels and start oxygen therapy for a Pao2

 Pulsatile hepatomegaly

due to left heart disease, (3) PH due to lung disease, or

class IV is the most severe ( Ricketts & Church, 2017).

 Make sure that patients are eating their meals as nutritional
deficiencies have been seen with PAH (Vinke, Jansen, Witkamp,

can develop when the right heart chambers hypertrophy, and the

management in pulmonary arterial hypertension. European Respiratory Review,

Systemic consequences of pulmonary hypertension and right-sided heart failure.

with an imbalance of vasoconstricting and vasodilating substances in the small

progresses

• There are 5 types of pulmonary hypertension (PH), according

• The WHO recognizes 4 functional classes in PH. Functional

 Nurses caring for PAH patients need to monitor for complications

pulmonary vascular resistance (PVR), which causes right ventricular hypertrophy

 Exertional syncope and angina is seen as the disease

Graarup, J., Ferrari, P., & Howard, L. S. (2016). Patient engagement and self-

https://ghr.nlm.nih.gov/condition/pulmonary-arterial-hypertension#genes

 Exercise intolerance

at rest (Pristera, Musarra, Schilz, & Hoit, 2015).

Hoit, 2015).

for pump malfunction or drug disconnections as an interruption

the pulmonary artery and the heart’s right ventricle go up to overcome the increased

arterial pressure (mPAP) greater than or equal to 25 mm Hg

unclear multifactorial means (Pristera, Musarra, Schilz, &

 Always have a backup IV pump, and an extra drug on the unit

patients usually present with (Ricketts & Church, 2017).

Powell, 2019).

to the World Health Organization. They are (1) PAH, (2) PH

proper monitoring of patients receiving treatment with

arteries’ diameter, which leads to resistance. To compensate for the resistance, BP in

left ventricular dysfunction, or pericardial effusion (Leeper &
• PAH is defined hemodynamically as a mean pulmonary

the disease and current therapies. The focus should be on

and symptoms initially, but the following are the symptoms

PAH. Echocardiography is also used to assess the existence

and cardiac causes of PAH, such as valvular heart disease,

 Nurses who take care of PAH patients need to be educated on

in the drug’s flow can cause life-threatening rebound elevation in

standard for the diagnosis of PAH, can be used to diagnose

of right ventricular (RV) or right atrial enlargement or dilation

at the right time (Graarup, Ferrari, & Howard, 2016).
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